Developing Clinically Relevant Acquired Chemoresistance Models in Epithelial Ovarian Cancer Cell Lines.

Shenoy, Priti S; Chakraborty, Sourav; Gaikwad, Snehal M; Sakpal, Asmita; Ray, Pritha

Shenoy, Priti S; Chakraborty, Sourav; Gaikwad, Snehal M; Sakpal, Asmita; Ray, Pritha.

Afiliación

Shenoy PS; Imaging Cell Signalling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, TMC, Navi Mumbai, 410210, India.
Chakraborty S; Homi Bhabha National Institute, Anushakti Nagar, Mumbai, 400094, India.
Gaikwad SM; Imaging Cell Signalling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, TMC, Navi Mumbai, 410210, India.
Sakpal A; Homi Bhabha National Institute, Anushakti Nagar, Mumbai, 400094, India.
Ray P; Laboratory of Cancer Biology and Genetics, National Cancer Institute, NIH, Bethesda, Washington D.C., USA.

Bio Protoc ; 12(3): e4310, 2022 Feb 05.

Article en En | MEDLINE | ID: mdl-35284594

Palabras clave

Chemoresistance; Cisplatin; Metformin; Modified pulse method; Ovarian Cancer; Paclitaxel

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Bio Protoc Año: 2022 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google